Helixmith Co., Ltd.

ACTIVE

21 Meogok 8-ro 7-gil, Gangseo-gu, Seoul, South Koreahelixmith.comPublic75 employeesEstablished: 1996-01-01

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1996

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

33.3%

Phase 2

33.3%

Phase 3

23.8%

Not Applicable

4.8%

Trial Status Distribution

Completed

61.9%

Recruiting

9.5%

Terminated

4.8%

Withdrawn

23.8%

Clinical Trials

Trials sponsored by this organization (21)

A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis

Phase 2

Completed

interventional

Nov 20218 participants

A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Phase 3

Completed

interventional

May 2021106 participants

The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19

Phase 2

Withdrawn

interventional

May 2021100 participants

Clinical trial for TADIOS as supplemental therapy in mild to moderate COVID-19

Recruiting

interventional

Mar 2021100 participants

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

Phase 2

Completed

interventional

Mar 202118 participants

Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy

Phase 3

Completed

interventional

Nov 2020162 participants

The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

Phase 1

Completed

interventional

Sep 202012 participants

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Phase 3

Completed

interventional

Feb 2019101 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations